AR063345A1 - N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)-piperidin-4-iliden)metil) benzamida para el tratamiento del dolor, ansiedad y depresion - Google Patents

N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)-piperidin-4-iliden)metil) benzamida para el tratamiento del dolor, ansiedad y depresion

Info

Publication number
AR063345A1
AR063345A1 ARP070104641A ARP070104641A AR063345A1 AR 063345 A1 AR063345 A1 AR 063345A1 AR P070104641 A ARP070104641 A AR P070104641A AR P070104641 A ARP070104641 A AR P070104641A AR 063345 A1 AR063345 A1 AR 063345A1
Authority
AR
Argentina
Prior art keywords
methyl
quinolin
benzamide
piperidin
hydroxyethyl
Prior art date
Application number
ARP070104641A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR063345A1 publication Critical patent/AR063345A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

N-(2-hidroxietil)-N-metil-4-(quinolin-8-iI(1-(tiazol-4-ilmetil)piperidin-4-iliden)metil)benzamida, sales aceptables para uso farmacéutico de la misma y/o mezclas de las mismas, como asi también composiciones farmacéuticas de las mismas, métodos de tratamiento con las mismas y procesos para preparar N-(2-hidroxietil)-N-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)piperidin-4-iliden)metil)-benzamida e intermediarios de la misma.
ARP070104641A 2006-10-20 2007-10-19 N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)-piperidin-4-iliden)metil) benzamida para el tratamiento del dolor, ansiedad y depresion AR063345A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86232706P 2006-10-20 2006-10-20

Publications (1)

Publication Number Publication Date
AR063345A1 true AR063345A1 (es) 2009-01-21

Family

ID=39314285

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104641A AR063345A1 (es) 2006-10-20 2007-10-19 N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)-piperidin-4-iliden)metil) benzamida para el tratamiento del dolor, ansiedad y depresion

Country Status (33)

Country Link
US (2) US7659286B2 (es)
EP (1) EP2079735B1 (es)
JP (1) JP4668346B2 (es)
KR (1) KR20090065534A (es)
CN (1) CN101528739B (es)
AR (1) AR063345A1 (es)
AT (1) ATE543818T1 (es)
AU (2) AU2007313515B2 (es)
BR (1) BRPI0717631A2 (es)
CA (1) CA2667041C (es)
CL (1) CL2007003009A1 (es)
CO (1) CO6180450A2 (es)
CY (1) CY1112718T1 (es)
DK (1) DK2079735T3 (es)
ES (1) ES2379519T3 (es)
HK (1) HK1131556A1 (es)
HR (1) HRP20120344T1 (es)
IL (1) IL197876A0 (es)
MX (1) MX2009003974A (es)
MY (1) MY148880A (es)
NO (1) NO20091969L (es)
NZ (1) NZ577060A (es)
PE (2) PE20080892A1 (es)
PL (1) PL2079735T3 (es)
PT (1) PT2079735E (es)
RS (1) RS52260B (es)
RU (1) RU2454414C2 (es)
SA (1) SA07280549B1 (es)
SI (1) SI2079735T1 (es)
TW (1) TW200826939A (es)
UA (1) UA97648C2 (es)
UY (1) UY30652A1 (es)
WO (1) WO2008048171A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007503457A (ja) * 2003-05-16 2007-02-22 アストラゼネカ・アクチエボラーグ ジアリールメチリデンピペリジン誘導体、その製造およびその使用
MY148880A (en) 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
NZ590041A (en) * 2008-05-20 2012-11-30 Astrazeneca Ab Method of treating anxious major depressive disorder
CN101906078B (zh) * 2009-06-08 2012-02-01 上海威智医药科技有限公司 噻唑衍生物的合成方法
CN102106807B (zh) * 2009-12-29 2013-03-27 上海中西制药有限公司 一种固体制剂的制备方法及所得固体制剂
WO2020061165A1 (en) 2018-09-21 2020-03-26 Garland Industries, Inc. Helical hardbanding

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2898339A (en) * 1957-07-29 1959-08-04 Wm S Merrell Co N-substituted benzhydrol, benzhydryl, and benzhydrylidene piperidine
US4581171A (en) * 1983-07-27 1986-04-08 Janssen Pharmaceutica, N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones useful for treating psychotropic disorders
TW548271B (en) 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
AU2009799A (en) * 1997-12-24 1999-07-19 Ortho-Mcneil Pharmaceutical, Inc. 4-(aryl(piperidin-4-yl)) aminobenzamides which bind to the delta-opioid receptor
US6492375B2 (en) * 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
SE9904673D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
JP2003518107A (ja) 1999-12-20 2003-06-03 ニューロメド テクノロジーズ， インコーポレイテッド 部分飽和カルシウムチャネルブロッカー
AU2001241676A1 (en) * 2000-03-03 2001-09-17 Ortho-Mcneil Pharmaceutical, Inc. 3-(diarylmethylene)-8-azabicyclo(3.2.1)octane derivatives
SE0001208D0 (sv) * 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
SE0101768D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
US20040204404A1 (en) * 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
SE0300105D0 (sv) * 2003-01-16 2003-01-16 Astrazeneca Ab Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof
SE0301445D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301444D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301441D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301442D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations therof and uses thereof
JP2007503457A (ja) * 2003-05-16 2007-02-22 アストラゼネカ・アクチエボラーグ ジアリールメチリデンピペリジン誘導体、その製造およびその使用
SE0400025D0 (sv) * 2004-01-09 2004-01-09 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
MY148880A (en) 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression

Also Published As

Publication number Publication date
HRP20120344T1 (hr) 2012-05-31
MX2009003974A (es) 2009-04-27
RS52260B (en) 2012-10-31
PT2079735E (pt) 2012-05-07
JP4668346B2 (ja) 2011-04-13
PE20140634A1 (es) 2014-06-19
ES2379519T3 (es) 2012-04-26
EP2079735A1 (en) 2009-07-22
CY1112718T1 (el) 2016-02-10
ATE543818T1 (de) 2012-02-15
SI2079735T1 (sl) 2012-05-31
AU2007313515B2 (en) 2010-11-25
CA2667041A1 (en) 2008-04-24
US7659286B2 (en) 2010-02-09
RU2009111337A (ru) 2010-11-27
SA07280549B1 (ar) 2010-09-29
JP2010506910A (ja) 2010-03-04
CN101528739A (zh) 2009-09-09
AU2010226996A1 (en) 2010-10-28
NO20091969L (no) 2009-05-20
PE20080892A1 (es) 2008-09-11
RU2454414C2 (ru) 2012-06-27
NZ577060A (en) 2011-01-28
EP2079735A4 (en) 2010-12-29
AU2007313515A1 (en) 2008-04-24
BRPI0717631A2 (pt) 2013-10-29
IL197876A0 (en) 2009-12-24
US7977355B2 (en) 2011-07-12
CN101528739B (zh) 2011-11-30
UA97648C2 (ru) 2012-03-12
UY30652A1 (es) 2008-05-31
KR20090065534A (ko) 2009-06-22
DK2079735T3 (da) 2012-05-21
US20080182875A1 (en) 2008-07-31
EP2079735B1 (en) 2012-02-01
CA2667041C (en) 2011-09-06
CL2007003009A1 (es) 2008-06-06
PL2079735T3 (pl) 2012-07-31
WO2008048171A1 (en) 2008-04-24
US20100160374A1 (en) 2010-06-24
MY148880A (en) 2013-06-14
HK1131556A1 (es) 2010-01-29
CO6180450A2 (es) 2010-07-19
TW200826939A (en) 2008-07-01

Similar Documents

Publication Publication Date Title
PE20211478A1 (es) Formas cristalinas novedosas
CL2008002162A1 (es) Compuestos derivados de 3-benzoisoxazol-piperidin; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de trastornos cognitivos, adiccion a drogas, depresion, ansiedad, entre otras.
CL2008002998A1 (es) Compuestos derivados de piperazina-1-carboxamida, inhibidor de faah; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor inflamatorio o neuropatico, ansiedad y depresion.
ECSP099476A (es) Compuestos carboxamida y su uso como inhibidores de calpaína
CL2008002622A1 (es) 1-(1-metiletil)-4-{[4-(tetrahidro-2h-piran-4-iloxi)fenil]carbonil}piperazina y su sal hidrocloruro; formas cristalinas de la sal; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento o profilaxis de deterioro cognitivo, fatiga o trastorno del sueno.
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
ATE459603T1 (de) Pyridinaminosulfonylsubstituierte benzamide als inhibitoren von cytochrom p450 3a4 (cyp3a4)
AR063345A1 (es) N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)-piperidin-4-iliden)metil) benzamida para el tratamiento del dolor, ansiedad y depresion
UY30048A1 (es) Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
CR11416A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
CU23779B7 (es) Compuestos de pirazolina y su uso y composiciones farmacéuticas
AR053169A1 (es) Metabolitos de n-2 (cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil) -2-metil -4-pi rimidinil] amino]-5-tiazol carboxamidas
CL2011000544A1 (es) Compuestos derivados de benzamida n sustituida por heterociclo, ligandos de los receptores cannabinoides; composicion farmaceutica; y su uso para tratar el dolor, entre otras enfermedades.
NO20072005L (no) Nye heterocykliske amider
AR054779A1 (es) N-(2,2-dimetilpropil)-6-{3-fluoro-5-[(3-isoxazolilamino)carbonil]-2-metilfenil}-3-piridinacarboxamida
DOP2006000024A (es) Tiazolidinonas, su preparación y su uso como medicamento
UY28993A1 (es) Tetrahidroisoquinolinas sustituidas en calidad de inhibidores de mpm, procedimiento para su uso como medicamento.-
CL2007003043A1 (es) Compuestos derivados de cromano; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y ansiedad entre otros.
CO6390054A2 (es) Formas cristalinas de un compuesto 3-carboxipropil-aminotetralina
CL2004000730A1 (es) Compuestos derivados de 4-[2-(fenilsulfanil sustituido)fenil]-1,2,3,6-tetrahidropiridina; composicion farmaceutica que los contiene; y su uso para el tratamiento de trastornos afectivos, tales como la depresion, trastornos de ansiedad, de ansiedad so
CL2007003396A1 (es) Uso de agomelatina o n-[2-(7-metoxi-1-naftil)etil]acetamida para el tratamiento del sindrome de smith magenis; composicion farmaceutica que contiene agomelatina.
UY29470A1 (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos bipolares
CL2007003426A1 (es) Compuestos derivados de dialquilaminoalquilo de pigavabina; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos afectivos, depresivos, de ansiedad.
CL2008003047A1 (es) Compuestos derivados de n-(2- fluoro-3-alquiloxifenil)metilquinolina-6- carboxamida; agente controlador de enfermedades de las plantas que contiene a dichos compuestos; metodo para controlar enfermedades de las plantas; uso de dichos compuestos; y compuestos intermediarios.
CL2009000050A1 (es) Compuestos derivados de 3-fluoro-4[4-[2-(3,5-dimetilfenil)pirrolidin-1-il]-metil]fenoxi]benzamida; composicion farmaceutica; y su uso para el tratamiento de trastorno de uso de alcohol etilico, trastorno de ansiedad, enfermedad depresiva, esquizofrenia, entre otras.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal